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Background. Coronary artery calcification is a common fea-
ture of atherosclerosis, occurring in 90% of angiographically
significant lesions. There is recent evidence that coronary artery
calcification is frequent in hemodialysis patients and it has been
suggested that this increased incidence may be associated to
uremia-related factors. The development and progression of
coronary artery calcification is similar to osteogenesis. The aim
of this study was to evaluate the relationship between coronary
artery calcification, uremia-related factors, and bone histomor-
phometry in hemodialysis patients.
Methods. A total of 101 hemodialysis patients were assessed
for biochemical markers of inflammation, oxidative stress, and
bone metabolism. Subsequently, they were submitted to multi-
slice coronary tomography (MSCT) and transiliac bone biopsy.
Results. The median calcium score was 116.2 (range 0 to 5547).
Fifty-two percent of the patients showed moderate and severe
coronary artery calcification, 20% had calcium scores greater
than 1000. In univariate analysis, age (r = 0.57, P < 0.000001),
osteoprotegerin (OPG) (r = 0.44, P = 0.00002), and body mass
index (BMI) (r = 0.24, P = 0.01) correlated positively with cal-
cium score. Bone trabecular volume and trabecular thickness
correlated negatively with calcium score (r = −0.24, P = 0.02;
r = −0.22, P = 0.03). There was a correlation of borderline sig-
nificance between calcium score and C-reactive protein (CRP)
(r = 0.18, P = 0.062). The multiple linear regression analysis
identified OPG as the only variable independently associated
with coronary artery calcification.
Conclusion. Coronary artery calcification is highly prevalent
in the hemodialysis population and is associated with older age,
higher BMI, inflammation and reduced trabecular bone volume.
Higher OPG is independently associated with coronary artery
calcification and may represent an incomplete self-defensive
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response to the progression of atherosclerosis in hemodialysis
patients.
Cardiovascular disease is responsible for more than
50% of deaths among patients with end-stage renal dis-
ease (ESRD) [1]. In patients treated by hemodialysis, the
prevalence of coronary artery disease is approximately
40%, and the risk of dying from a cardiovascular event is
20-fold greater than the risk observed in the general pop-
ulation [2, 3]. The high prevalence of classic cardiovascu-
lar risk factors, such as hypertension, dyslipidemia, and
diabetes, cannot fully explain this exceptionally increased
incidence of coronary artery disease. Recently, factors
related to uremia and the hemodialysis treatment itself,
like hyperhomocysteinemia, increased oxidative stress,
altered mineral metabolism, and chronic inflammation,
have been proposed to play a role in the pathogenesis of
coronary artery disease in uremic patients [4].
In the last two decades, noninvasive techniques have
been introduced for the routine diagnosis of coronary
artery disease. These techniques allow the measurement
of calcium deposits within the coronary arteries, and in-
clude electron-beam tomography (EBT) and multislice
coronary tomography (MSCT).
Previous studies demonstrated an association between
vascular calcification and osteoporosis, which was eval-
uated through bone mineral density. There is evidence
that low bone mineral density in the hip is a marker of
advanced atherosclerosis in elderly women [5]. In chronic
kidney disease patients, bone mineral density has limita-
tions when compared to bone histomorphometry to eval-
uate renal osteodystrophy [6, 7]. A recently published
study has demonstrated a relationship between bone his-
tomorphometric findings and arterial calcification in ure-
mic patients [8].
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The aim of the present study was to evaluate the
prevalence of coronary artery calcification by MSCT in
hemodialysis patients, and to address the associations
among coronary artery calcification and dyslipidemia, in-
flammation, oxidative stress, bone biochemical markers,
and bone histomorphometry in this population.
METHODS
Subjects and study design
One hundred and one adult patients (age >18 years)
on maintenance hemodialysis, for at least 3 months, at
four dialysis centers in Sa˜o Paulo, Brazil, were studied.
The present study refers to the baseline data of an on-
going randomized clinical trial comparing two phosphate
binders, sevelamer and calcium acetate, in hemodialy-
sis patients. Exclusion criteria included serious gastroin-
testinal disease, ethanol or drug abuse, active malignancy,
human immunodeficiency virus (HIV) infection, chronic
inflammatory disease, use of steroids, severe hyper-
parathyroidism [defined as intact parathyroid hormone
(iPTH) >1000 pg/mL], body weight >100 kg, continu-
ous use of antiarrhythmic or seizure drugs, pregnancy
or breast-feeding, previous myocardial revasculariza-
tion, uncontrolled diabetes mellitus, or hypertension (as
deemed by the investigator). After screening, subjects un-
derwent a 2-week washout period, in which all phosphate
binders were withheld. Patients with hyperphosphatemia
(serum phosphorus >5.5 mg/dL) during the washout pe-
riod were eligible. All patients received hemodialysis
three times weekly, for at least 4 hours, using hollow fiber
polysulphone or celulose acetate membranes. Native ar-
teriovenous fistula was the vascular access type in 92% of
the patients. Regarding renal osteodystrophy treatment,
in the month before enrollment, 15 patients were on reg-
ular use of oral calcitriol, eight of them intermittently
(0.25 to 2 lg/hemodialysis), and seven daily (0.25 to 0.5
lg/day) and 95 patients took calcium-containing phos-
phate binders (either calcium acetate or carbonate). At
this time, no patient was receiving either sevelamer or
aluminum hydroxide as phosphate binders.
In a cross-sectional design, the demographic, dialysis-
specific, and clinical characteristics of the selected pa-
tients were obtained. Nutritional status of all patients
was evaluated by subjective global assessment and pa-
tients were classified as well-nourished, mild to moder-
ately malnourished, or severely malnourished [9]. The
risk of developing coronary heart disease according to
the Framingham risk index was estimated for each pa-
tient, as described elsewhere [10]. Blood samples were
drawn in the same period. Subsequently, the patients un-
derwent a MSCT as described below. In order to verify
long-term alterations on mineral homeostasis that could
be related to coronary artery calcification, a bone biopsy
was performed. All patients signed an informed consent.
The study protocol was reviewed and approved by the
local institutional ethics board.
Biochemical analysis
Whole blood was collected at the respective study sites
by vein puncture in a fasting state the morning before the
first weekly hemodialysis session. Laboratory evaluation
included blood count determination, measurements of
ionized calcium, phosphorus, alkaline phosphatase (ref-
erence ranges <270 U/L for male and <240 U/L for fe-
male), iPTH (chemoluminescent substract, DPC) (Med-
lab, Los Angeles, CA, USA) (reference range 10 to 65 pg/
mL), 25-(OH) vitamin D (radioimmunoassay) (Dia-
Sorin) (Stillwater, MN, USA) (reference range 18 to
62 ng/dL), osteoprotegerin (OPG) [enzyme-linked im-
munosorbent assay (ELISA)] (Immundiagnostik Labo-
ratory, Bensheim, Germany) (reference range 30.45 ±
12.1 pg/mL), soluble RANKL (ELISA) (Immundiag-
nostik Laboratory) (detection limit 1.5 pg/mL), al-
bumin, C-reactive protein (CRP) (High Sensitive C-
Reactive Protein Immunolite) (immunometric assay)
(functional sensibility <0.2 mg/L), homocysteine [high-
pressure liquid chromatography (HPLC)] (reference
range 5 to 17 mmol/L), and anti-oxized low-density
lipoprotein (oxLDL) antibody (Anti-oxLDL antibody
ELISA) (IMMCO Diagnostics, Buffalo, NY, USA) (ref-
erence range <20 EU/mL = negative, 20 to 25 EU/mL =
indeterminate, and >25 EU/mL = positive).
Imaging procedure
Calcification score was evaluated using MSCT (Soma-
tron Volum Zoom Siemens AG) (Erlhagen, Germany).
A chest radiologic image without contrast was acquired
while the subject was in apnea in order to determine the
initial and final level of the tomography. Images of each
section were then acquired, during a 150 msec exposure,
with a distance of 3 mm between each slice. The timing
of the image acquisition was coordinated with the dias-
tolic phase of the cardiac cycle, at 60% of the RR inter-
val, with the use of electrocardiograph monitoring. All
obtained scans were analyzed with the use of a “Work-
station” (Indigo 02 SGI, Mountain View, CA, USA)
in order to determine the calcium score. The software
can detect calcified lesions with a density of at least 130
Hounsfield units and minimal 0.5 mm2 area. Total calcium
score calculation was based on formulas using measure-
ment of total volume and area of calcified lesions, as well
as mean and maximum density. The total score was the
sum of each coronary score and was expressed in modified
Agatston et al [11] and Janowitz et al [12] units. The clas-
sification proposed by Rumberger et al [13] was used for
descriptive purposes: calcium scores <10 indicate min-
imal atherosclerotic plaque, calcium scores between 11
and 100 indicate mild plaque burden, calcium scores be-
tween 101 and 400 indicate moderate plaque burden, and
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calcium scores higher than 400 indicate severe and exten-
sive plaque burden.
Bone biopsy
Bone biopsies were carried out in either the right or left
iliac crest, using a 7 mm inner diameter electrical trephine
(Gauthier Medical, Rochester, MN, USA). All patients
were prelabeled with oral tetracycline (20 mg/kg/day for
3 days) administered over two separated periods, 10 days
apart. Bone fragments were submitted to the usual pro-
cessing and histologic studies [14]. Sections were stained
with toluidine blue staining. Bone histomorphometry was
conducted using the semiautomatic method contained in
the software Osteomeasure (Osteometrics Inc., Atlanta,
GA, USA). The static and dynamic parameters were an-
alyzed in accordance with the standards of the American
Society of Bone and Mineral Research [15].
On the basis of the histomorphometry, the patients
were classified into the following groups: (1) predominant
hyperparathyroid bone disease, defined as bone forma-
tion rate, plus either osteoblast or osteoclast surface more
than one SD above normal range, osteoid volume within
or above the normal range, and marrow fibrosis > 0.5%;
(2) adynamic bone disease, defined as bone formation
rate and osteoid volume more than one SD below the nor-
mal range and marrow fibrosis <0.5%; (3) osteomalacia,
defined as bone formation rate more than one SD below
the normal range plus osteoid volume more than one SD
above the normal range; (4) mixed renal osteodystrophy,
defined as bone formation rate more than one SD below
the normal range, osteoid volume and osteoblast surface
more than one SD above the normal range, and marrow
fibrosis ≥0.5%; and (5) isolated osteopenia, defined as
trabecular bone volume more than one SD bellow the
normal range with the other parameters within the nor-
mal range.
The reference ranges for bone formation rate are
0.07 ± 0.03 l3/l2/day (female)/0.13 ± 0.07 l3/l2/day
(male); osteoblast surface are 1.4 ± 3.0% (female)/2.13 ±
3.8% (male); osteoclast surface are 0.04 ± 0.08% (fe-
male)/0.07 ± 0.22% (male); osteoid volume are 1.58 ±
1.8% (female)/3.2 ± 3.0% (male); and trabecular bone
volume are 22 ± 7.3% (female)/25.5 ± 8.1% (male).
Statistical analysis
Demographic characteristics were described using
mean ± standard deviation, median (range) and propor-
tions. Regarding renal osteodystrophy, a chi-square test
was performed to assess the association between each di-
agnostic pattern with the presence of coronary artery cal-
cification. Mann-Whitney U test was taken to evaluate the
differences in calcium score among these subgroups. The
association between calcium score and other variables
was assessed using the Spearman correlation coefficient.
Table 1. Demographic, clinical and laboratorial characteristics of the
patients (N = 101)
Age years 48 ± 13 (21–81)
Race white/nonwhite 57/44
Etiology of end-stage renal disease
Unknown% 28
Hypertension% 27
Chronic glomerulonephritis% 19
Diabetes mellitus% 9
Others% 18
End-stage renal disease diagnosis 64 ± 65 (6–336)
months
Length on hemodialysis 37 ± 25 (4–103)
months
Body mass index kg/m2 25 ± 4.3 (17.4–36.6)
Comorbid conditions
Hypertension% 70
Diabetes mellitus% 16
Smoking% 25
Hemoglobin g/dL 11.3 ± 1.6 (6.4–15.3)
Kt/V 1.3 ± 0.2 (0.64–1.9)
Cholesterol mg/dL 165.4 ± 41.7 (89–308)
High-density lipoprotein cholesterol 42 ± 10.4 (20–71)
mg/dL
Low-density lipoprotein cholesterol 91.3 ± 29.6 (28–161)
mg/dLa
Very low-density lipoprotein 29.5 ± 15.8 (7–79)
cholesterol mg/dLa
Triglycerides mg/dL 156.5 ± 93.4 (34–489)
Homocysteine mmol/Lb 41 ± 35.1 (10.4–160.2)
Albumin g/dL 3.8 ± 0.2 (3.2–4.5)
C-reactive protein mg/L 9.8 ± 16.3 (0.5–129)
Antioxidized low-density lipoprotein 27.3 ± 22.1 (0–126)
EU/mLc
Ionized calcium mmol/L 1.24 ± 0.08 (0.96–1.45)
Phosphorus mg/dL 7.22 ± 1.8 (5.5–19.2)
Alkaline phosphatase U/L 245.3 ± 152.5 (88–1155)
Intact parathyroid hormone pg/mL 351.3 ± 310.1 (9–1266)
25-(OH) vitamin D3 ng/dLc 32.8 ± 14.7 (11.2–94.4)
Osteoprotegerin pg/mLc 174.7 ± 71.7 (42.2–434.8)
sRANK-L pg/mLc 5.4 ± 8.7 (1.5–50.6)
sRANK-L is soluble receptor activator of NF-KappaB ligand. Values
expressed as mean ± SD (range) and proportions.
aN = 98; bN = 99; cN = 87.
Multiple linear regression analysis was conducted to in-
vestigate whether the extent of calcification was related to
any demographic, clinical, laboratory, or bone histomor-
phometric variables. A P value < 0.05 was considered
significant. All statistical analysis was carried out using
the true Epistat program (Epistat Services, Richardson,
TX, USA).
RESULTS
Demographic, clinical and laboratorial characteristics
of the 101 patients studied are listed in Table 1. The pa-
tients were young and had been undergoing hemodialysis
treatment for an average of 3 years. Although nephroscle-
rosis was the cause of ESRD in 27% of our patients, 70%
had hypertension as a comorbid condition, and 16% had
diabetes. The majority of the patients (75%) were consid-
ered well nourished as evaluated by the subjective global
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Table 2. Histomorphometric characteristics (N = 98)
Trabecular bone volume % 16.6 (6.8–41.3)
Osteoid thickness lm 7.65 (2.8–18.5)
Osteoid surface % 21.8 (1.9–71)
Osteoblast % 2.75 (0–31.1)
Eroded surface % 4.0 (0–25.3)
Osteoclast % 0.7 (0–4)
Trabecular thickness lm 111.8 (77.3–159.7)
Trabecular separation lm 534.25 (197–1526.8)
Travecular number mm 1.55 (0.6–7.31)
Fibrosis volume % 0.04 (0–2.9)
Mineralizing surface % 2.1 (0–20.6)
Mineral apposition rate l/day 0.70 (0–1.9)
Bone formation rate l2/l3/day 0.02 (0–0.39)
Ajusted apposition rate l/day 0.09 (0–1)
Mineralization lag time days 45.2 (7–494.5)
Values expressed as median (range).
assessment. Overweight or obesity was observed in 51%
[body mass index (BMI) >25] of patients.
Total cholesterol levels higher than 200 mg/dL were
observed in 17% of the patients, low-density lipopro-
tein (LDL) cholesterol >100 mg/dL in 33%, high-density
lipoprotein (HDL) cholesterol <40 mg/dL in 49%, and
triglycerides >150 mg/dL in 39% of them. All but one
patient had hyperhomocysteinemia (Hcy) >14 mmol/L.
The mean values of CRP and antibody against oxLDL
were increased. CRP greater than 1.1 mg/L was observed
in 93% of the patients, and 61% had CRP 5.0 mg/L. Anti-
body against oxLDL was positive in 44% of the patients.
As expected, all patients showed hyperphosphatemia.
The mean values of alkaline phosphatase, iPTH and 25-
(OH) vitamin D were close to those normally observed
in hemodialysis patients. However, there was great vari-
ability in these results. In fact, 33% of the patients had
an iPTH <150 pg/mL and 39% had an iPTH greater than
300 pg/mL.
Table 2 lists the histomorphometric characteristics. All
patients were submitted to bone biopsy, but three of the
bone fragments were not adequate for histologic anal-
ysis. The distribution of renal osteodystrophy patterns,
according to histologic parameters, showed that the ma-
jority of the patients (56%) were classified as having
adynamic bone disease, 12% osteitis fibrosa, 21% mixed
renal osteodystrophy, 3% osteomalacia, 3% isolated
osteopenia, and 4% normal bone. It is notable that, in
general, patients were asymptomatic regarding the os-
teoarticular system.
The coronary calcium score is described in Table 3.
Median calcium score was 116.2 (range 0 to 5545.7). Fifty-
two percent of the patients showed moderate to severe
calcification. Twenty percent of the patients had calcium
scores greater than 1000 and 28% had calcium score = 0.
There was no association between the presence of coro-
nary artery calcification (calcium score >10) and any of
the different patterns of renal osteodystrophy.
Table 3. Coronary calcification (N = 101)
Rumberger classification %
10–100 14
101–400 21
>400 31
Values expressed as median (range) and proportions.
Table 4. Coronary calcification correlations
Univariate r P value
Age 0.57 <0.000001
Cardiovascular risk 0.56 <0.000001
(Framingham)
Osteoprotegerin 0.44 0.00002
Body mass index 0.24 0.01
Bone volume −0.24 0.02
Trabecular thickness −0.22 0.03
C-reactive protein 0.18 0.062
Multivariate b coefficient P value 95% CI
Osteoprotegerin 7.28 0.00018 3.59–10.99
Table 4 shows the results of univariate and multivariate
analyses. When clinical parameters and blood chemistries
were considered as a function of calcification, only age,
Framingham risk index, OPG, and BMI were significantly
associated with higher calcification scores (Fig. 1). More-
over, the histomorphometric parameters trabecular bone
volume and trabecular thickness were negatively corre-
lated with calcification score. There was a correlation of
borderline significance between CRP and calcium score.
In the multivariate regression analysis, the only indepen-
dent determinant of calcium score was OPG.
No association was observed between calcium score
and phosphorus, ionized calcium, calcium-phosphorus
product, iPTH, vitamin D, lipid profile, homocysteine,
anti-oxLDL antibody, demographic, or clinical charac-
teristics.
DISCUSSION
This study shows a high prevalence of coronary artery
calcification in relatively young ESRD patients undergo-
ing hemodialysis. The importance of this finding relies on
the fact that the majority of significant atherosclerotic
lesions are calcified [16] and previous studies demon-
strated that coronary artery calcification is a predictor of
coronary artery disease in persons with and without re-
nal failure [17–19]. Watson et al [20], studying nonuremic
individuals with high risk of developing coronary artery
disease, concluded that vascular calcification detected by
EBT occurred in more than 90% of the patients with
significant angiographic lesions. Detrano et al [21] con-
ducted a follow-up study of 30 ± 13 months on 491 pa-
tients without renal disease submitted simultaneously to
coronary angiography and EBT. Patients with calcium
score greater than 75.3 (median) showed sixfold higher
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Fig. 1. Correlation between osteoprotegerin
and calcium score in 87 patients.
risk of suffering a myocardial infarction or cardiac death.
Marwick et al [19] followed 1173 patients for an aver-
age of 19 months after EBT screening. The odds ratio of
cardiac event for a calcium score >160 was 35.4%.
In the present study, median calcification score was
116.2 and 31% of the patients had calcium scores higher
than 400, which suggest severe and extensive atheroscle-
rotic disease. This is in accordance with the study
performed by Braun et al [22] comparing calcium scores
detected by EBT in hemodialysis patients and nondialysis
patients with suspected or documented coronary artery
disease. The hemodialysis patients showed 2.5- to fivefold
higher calcium scores and progression of the coronary
artery calcification within 1 year. It has also been ob-
served that in young hemodialysis patients (<30 years)
coronary artery calcification is a common finding and the
rate of progression exceeds the rate observed in older
persons with normal renal function [23].
As demonstrated by other authors [22, 24, 25], we ob-
served that older age was associated with higher coronary
calcium scores. Other traditional risk factors were highly
prevalent in the population studied. Hypertension was a
comorbid condition observed in 70% of the patients and
49% of the studied population presented at least one al-
tered lipid fraction. In spite of that, we could not observe
significant association between any of these variables
and coronary calcification. On the other hand, we found
that the Framingham risk index correlated significantly
with coronary calcium score. Possibly, the Framingham
risk reflects an association between the sum of above-
mentioned traditional risk factors and coronary calcifi-
cation in hemodialysis patients. However, because this
is a cross-sectional study, one cannot establish a causal
relationship. There was also a significant association be-
tween BMI and coronary calcium score, suggesting that
overweight may contribute to increasing coronary artery
calcification in this population.
Nontraditional risk factors have been proposed to con-
tribute to the high incidence of cardiovascular disease
in hemodialysis patients, including Hcy, oxidative stress,
and inflammation [26–28]. In our study, we observed a
high prevalence of Hcy (99.9%), however, it was not
correlated with coronary calcification. In previous large
epidemiologic studies, elevated serum CRP predicted
cardiovascular events and cardiovascular death in both
healthy and uremic individuals [29–32]. Recently, it has
been suggested that CRP may be one of the key mediators
of vessel wall calcification in hemodialysis patients [33].
In the present study, 93% of the patients had CRP levels
greater than 1.1 mg/L, which is associated with cardio-
vascular risk in the general population. We observed that
patients with higher CRP levels tended to have higher
coronary calcium scores.
It is also proposed that disorders of mineral metabolism
may play a role in the genesis of vascular calcification
in ESRD patients. Epidemiologic studies have demon-
strated a direct correlation between serum phosphorus
and calcium-phosphorus product and mortality, espe-
cially from cardiovascular causes, in hemodialysis pa-
tients [34, 35]. In a baseline cross-sectional analysis
of a prospective study conducted by Raggi et al [36],
serum phosphorus and calcium significantly positively
correlated with the severity of coronary artery calcifi-
cation. Other observational studies in ESRD patients
showed variable results concerning disorders of mineral
metabolism and coronary artery calcification [24, 37, 38].
Goodman et al [23] observed a significant association
between duration of dialysis, body-mass index calcium-
phosphorus product and the amount of daily-intake
of calcium-containing phosphate-binders and coronary
calcification score in young dialysis patients. Recently,
Chertow et al [39] demonstrated a relation between
PTH and the progression of coronary artery calcification
in hemodialysis patients, depending on the phosphate
binder used. Braun et al [22] found an inverse association
between the total coronary artery calcium content and
vertebral bone mass, confirming the important relation-
ship between abnormal calcium homeostasis and coro-
nary artery calcification in dialysis patients. In spite of
that, they did not observe an association between calcium,
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phosphorus, iPTH, or the treatment with vitamin D ana-
logues and the calcium score. Accordingly, in our study,
we found no association between coronary calcium score
and phosphorus, calcium, iPTH, alkaline phosphatase or
25-(OH) vitamin D.
The fact that all the patients studied were hyper-
phosphatemic and that severe hyperparathyroidism was
excluded (iPTH >1000 pg/mL) may have limited our ob-
servations about the association between coronary artery
calcification and alterations in the calcium-phosphorus
homeostasis. In the same way, as this is a cross-sectional
analysis, the biochemical data may not reflect the time-
averaged exposure to disorders of mineral metabolism.
On the other hand, the bone biopsy is still considered
as the gold standard for evaluating bone remodeling
alterations.
In this study, we found a high prevalence of adynamic
bone disease. This may reflect previous overtreatment
with vitamin D sterols and calcium containing phosphate
binders, or perhaps a high calcium burden from dialysate
fluid, as most patients (83%) were treated with a 1.75
mmol/L calcium concentration. It seemed to be a ten-
dency for patients with adynamic bone disease to have
higher calcium scores (N = 55) (median calcium score
115.2; 0 to 5545.7 arbitrary units) than patients with OF
(N = 12) (median calcium score 19.05; 0 to 1217 arbitrary
units), but there was great variability between patients,
and this difference did not reach statistical significance.
Although in this study we did not find any associa-
tion between the different bone histological diagnostic
patterns and the extent of coronary artery calcification,
when we analyzed each histomorphometric parameter,
we observed that trabecular bone volume and trabecu-
lar bone thickness correlated negatively with coronary
calcium score. Previous studies demonstrated the rela-
tionship between reduced bone mass and vascular cal-
cification in the elderly with osteoporosis and also in
hemodialysis patients [40, 22]. London et al [8] observed
an association between low bone activity as well as ady-
namic bone disease and arterial calcification evaluated
through ultrasononagraphy. In fact, vascular calcification
seems to be a process similar to bone formation that may
involve calcium mobilization from bone, excessive cal-
cium positive balance (from the dialysate fluid and or the
calcium-based phosphate binders), or a bone-buffering
capacity insufficient relatively to the amount of calcium
load [35, 41, 42].
In the present study, we observed that patients had
elevated OPG and multiple regression analysis showed
that OPG was the only independent variable associated
with coronary artery calcification. This is in accordance
with the study performed by Nitta et al [43], who con-
cluded that rapid progression of vascular calcification in
long-term hemodialysis patients was independently asso-
ciated with high OPG concentration. Kazama et al [44]
demonstrated that OPG levels are significantly higher in
uremic patients than in general population. In nonrenal
population, high serum OPG levels were associated with
the presence and severity of coronary artery disease [45].
OPG, a soluble decoy receptor of the tumor necrosis
factor family, seems to be a possible link between bone re-
modeling and vascular calcification. OPG is produced by
various tissues (bone, lung, kidney, immune tissues, car-
diovascular system) and is also expressed in endothelial
and smooth-muscle cells in vitro [46, 47]. This cytokine
increases mineral density and bone volume by decreas-
ing the number of active osteoclasts [48]. Transgenic mice
that overexpress OPG have osteoporosis [46] and it has
been shown that OPG-deficient mice develop severe os-
teoporosis and medial arterial calcification [49]. The con-
flicting findings between these experimental observations
and the above cited clinical studies could be explained by
an incomplete compensatory self-defensive response of
OPG to the progression of atherosclerosis [50].
This study evaluated simultaneously the role of tradi-
tional and nontraditional cardiovascular risk-factors, like
Hcy, increasing in oxidative stress, inflammation, and the
alterations on bone and mineral metabolism documented
by bone biopsies with the development of coronary artery
calcification in hemodialysis patients. We concluded that
coronary artery calcification is common and severe in this
population and is associated with aging, derangements of
mineral metabolism and chronic inflammation. Further
studies are needed to evaluate the apparently paradoxi-
cal effect of OPG on vascular calcification.
Reprint requests to Daniela Veit Barreto.
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